Seroepidemiology of hepatitis B virus infection among adults in Singapore: a 12-year review (Q38160646)

30 August 2017

Seroepidemiology of hepatitis B virus infection among adults in Singapore: a 12-year review (English)

1 reference

30 August 2017

0 references

1 reference

Li Wei Ang

1

0 references

author name string

Jeffery Cutter

series ordinal

2

1 reference

30 August 2017

Lyn James

series ordinal

3

1 reference

30 August 2017

Kee Tai Goh

series ordinal

4

1 reference

30 August 2017

language of work or name

English

0 references

publication date

5 November 2013

1 reference

30 August 2017

1 reference

30 August 2017

32

1 reference

30 August 2017

1

1 reference

30 August 2017

103-110

1 reference

Global control of hepatitis B virus infection.

30 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.057

Maternal-child hepatitis B virus transmission in Singapore

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.057

Seroprevalence of hepatitis B virus infection among children and adolescents in Singapore, 2008-2010.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.057

Epidemiology of hepatitis B infection in the Western Pacific and South East Asia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.057

Estimates of chronic hepatitis B virus infection in Australia, 2000.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.057

Trends in the seroprevalence of hepatitis B surface antigen in the South Korean population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.057

Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.057

Two decades of universal hepatitis B vaccination in taiwan: impact and implication for future strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.057

The prevalence of hepatitis B virus infection in the United States in the era of vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.057

Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects: sixteen years after newborn vaccination program in Taiwan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.057

Prevalence of hepatitis B virus (HBV) infection in Singapore men with sexually transmitted diseases and HIV infection: role of sexual transmission in a city state with intermediate HBV endemicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.057

Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.057

Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.057

Thirty-year outcomes of the national hepatitis B immunization program in Taiwan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.057

How big is the financial burden of hepatitis B to society? A cost-of-illness study of hepatitis B infection in Singapore.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.057

Economic evaluation of the societal costs of hepatitis B in South Korea.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.057

Persistence of specific antibodies after hepatitis B vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.057

Four-year experience with a recombinant hepatitis B vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.057

Are booster immunisations needed for lifelong hepatitis B immunity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.057

Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.057

Hepatitis B and the need for a booster dose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.057

Australia antigen in Singapore. II. Differential frequency in Chinese, Malays and Indians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.057

Ethnic differences in immune responses to hepatitis B vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.057

Ethnicity, substance use, and response to booster hepatitis B vaccination in anti-HBs-seronegative adolescents who had received primary infantile vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.057

Comparison of the results for three automated immunoassay systems in determining serum HBV markers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.057

Comparison of nine commercially available assays for quantification of antibody response to hepatitis B virus surface antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.057

Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.10.057

10.1016/J.VACCINE.2013.10.057

7 January 2021

Identifiers

DOI

1 reference

30 August 2017

1 reference